在喘管理中减少环境过敏原:概述
Duy Le Pham1,2, Kieu-Minh Le3, Diem D K Truong3
1Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Frontiers in allergy
|October 23, 2023
概括
控制喘包括避免环境过敏原,如灰尘和物皮毛. 识别和减少这些过敏原的暴露可以帮助控制喘症状并减少恶化.
科学领域:
- 过敏和免疫学的过敏和免疫学.
- 环境健康 环境健康
- 呼吸系统药物 呼吸系统药物
背景情况:
- 喘是一种常见的呼吸道疾病,影响所有年龄段的人,许多严重的病例无法通过药物控制.
- 对室内和室外过敏原等环境因素的过敏越来越多地与喘严重程度和症状有关.
- 常见的过敏原包括灰尘,,花粉,模具,物和动物,因地理区域而异.
研究的目的:
- 审查用于喘管理的环境过敏原避免策略.
- 为了澄清避免过敏原对喘控制的影响.
- 为突出识别过敏性喘患者的过敏原的重要性.
主要方法:
- 关于避免环境过敏原和控制喘的研究文献综述.
- 关于减少过敏原暴露对喘症状和恶化影响的证据分析.
- 综合了有关过敏原识别在喘管理中的作用的发现.
主要成果:
- 有证据表明,避免过敏原可能是对喘有益的非药物治疗方法.
- 减少对特定过敏原的暴露可能会降低喘症状和恶化风险.
- 避免过敏原策略的有效性可能会有所不同,研究中的结果有时是对比的.
结论:
- 识别环境过敏原对于患有喘的人来说至关重要.
- 需要进一步的研究,以建立临床有效的过敏原避免方法.
- 避免过敏原仍然是喘管理的关键组成部分,特别是在敏感的人群中.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
312
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
312
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma: Pathogenesis and Management
421
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
421
Drugs Used in Lower Respiratory Disorders: Overview
458
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
458
Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324


